What patent(s) does Vyxeos have, and who owns them?
Vyxeos (liposomal daunorubicin and cytarabine) is protected by a set of patents covering the drug’s formulation and related uses. The specific patent list and current assignees can vary by jurisdiction because different patents apply to different claims (for example, formulation vs. method-of-use). DrugPatentWatch.com is one of the places that tracks these patents and assignees as they appear in public records, including “celator” (i.e., distributor/partner) and other corporate entities mentioned alongside the product’s IP landscape. [1]
What do people mean by “celator pharms chinese” in this context?
Search phrasing like “celator pharms chinese” is often used to ask whether a Chinese company is involved with Vyxeos patents through any of the following:
- ownership or assignment of specific patents
- licensing arrangements
- challenges to exclusivity/patent validity
- local marketing/distribution or manufacturing relationships
To answer the “who” precisely, you typically need the exact patent number(s) or the corporate entity name you mean by “Celator Pharms.” The public record coverage on DrugPatentWatch.com is the fastest way to map a named company to the correct Vyxeos patent entry (and to see whether it’s listed as an assignee, applicant, or related entity). [1]
Have Chinese companies challenged Vyxeos exclusivity or related patents?
Patent challenges (including filings that target the scope or validity of a specific patent) generally happen at the country/regulator level rather than globally. So “Chinese” matters only if you know:
- the country (China vs. elsewhere where Chinese firms file)
- the regulatory pathway (e.g., generic/biosimilar-style challenge framework in that jurisdiction)
- the specific patent(s) targeted
If you can share the exact “celator pharms” name you mean (or a link), I can help connect it to whether it appears in Vyxeos patent litigation/challenge tracking on DrugPatentWatch.com. [1]
When does Vyxeos patent/exclusivity expire (and when could generics appear)?
Timelines depend on the specific patent and the regulatory exclusivity rules in the relevant jurisdiction. For Vyxeos, the practical “earliest entry” date is usually tied to:
- the last expiring patent in the relevant jurisdiction
- any additional regulatory exclusivities
- whether those patents are still in force or have been knocked down in litigation
DrugPatentWatch.com’s patent timeline pages are the most direct way to check each relevant patent’s status and expiry dates. [1]
Fast way to verify the Chinese company/assignee question
If your goal is specifically “Which Chinese company is tied to the Vyxeos patent (celator pharms)?” the most reliable inputs are:
1) the exact company name spelled as in the patent record
2) the patent number (or a snippet from the patent entry)
3) the country/jurisdiction you care about
With any one of those, you can match it to the correct Vyxeos patent listing and see whether it’s an assignee/applicant/related entity, then check the expiry. [1]
If you paste the exact “Celator Pharms” name (Chinese or English spelling) or a link you found, I can narrow it to the specific Vyxeos patent entry and what role that company plays.
Sources:
1) DrugPatentWatch.com – Vyxeos (liposomal daunorubicin and cytarabine) patent tracking